Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.57 |
| ▸ | USP7 | Q93009 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169616 | 0.88 | NOS2 (0.57) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL83736 | 0.88 | NOS2 (0.57) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Cddo-Cn SCHEMBL1146530 | 0.87 | NOS2 (0.78) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Cddo-Cn SCHEMBL1146531 | 0.87 | NOS2 (0.78) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Cddo-Cn SCHEMBL7716046 | 0.87 | NOS2 (0.78) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Cddo-Cn SCHEMBL10079615 | 0.87 | NOS2 (0.78) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10169627 | 0.87 | NOS2 (0.56) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Cddo-Cn SCHEMBL19335683 | 0.87 | NOS2 (0.78) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12958288 | 0.86 | NOS2 (0.46) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10169626 | 0.86 | NOS2 (0.55) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | Reata Pharmaceuticals Holdings, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-11-23 | — | — | US | disclosed |
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9556222-B2 | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9249089-B2 | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives | REATA PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9090574-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150148384-A1 | A-RING EPOXIDIZED TRITERPENOID-BASED ANTI-INFLAMMATION MODULATORS AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-RE45325-E1 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-RE45288-E1 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20110245233-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | REATA PHARMACEUTICALS, INC. | 2011-10-06 | — | — | US | disclosed |
| US-7943778-B2 | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives | REATA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7915402-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring | REATA PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110009363-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-7714012-B2 | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) | TRUSTEES OF DARTMOUTH UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | REATA PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100041904-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | REATA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20080261985-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | TRUSTEES OF DARTMOUTH COLLEGE | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333450-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED COGNITIVE DYSFUNCTION | CD14, CCL2, CCR5 | NOS2 14/4885KEAP1 107/4885CYP3A4 1565/4885 |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | TXNRD2, HMOX1, GPX4 | NOS2 83/4885KEAP1 60/4885CYP3A4 2104/4885 |
| US-20080261985-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | HMOX1, MCL1, HMOX2 | NOS2 7/4885KEAP1 38/4885CYP3A4 68/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20110009363-A1 | SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) | HMOX1, MCL1, HMOX2 | NOS2 7/4885KEAP1 38/4885CYP3A4 68/4885 |
| US-20100056777-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | HMOX1, ALOX12, ALOX15 | NOS2 25/4885KEAP1 56/4885CYP3A4 483/4885 |
| US-20100041904-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES | IL17A, ALOX15, ALOX12 | NOS2 65/4885KEAP1 45/4885CYP3A4 590/4885 |
| US-20100048911-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID | ALOX12, NFE2L2, HMOX1 | NOS2 66/4885KEAP1 29/4885CYP3A4 1940/4885 |
| US-20150148384-A1 | A-RING EPOXIDIZED TRITERPENOID-BASED ANTI-INFLAMMATION MODULATORS AND METHODS OF USE THEREOF | PTGES, PTGS1, PTGES2 | NOS2 43/4885KEAP1 54/4885CYP3A4 209/4885 |
| US-20110245233-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING | HMOX1, ALOX12, ALOX15 | NOS2 25/4885KEAP1 56/4885CYP3A4 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.